The COVID-19 pandemic has triggered additional considerations to supplier oversight.

Are Your Contract Manufacturing Facilities Up to Speed?

Outsourcing method development offers multiple benefits to companies.

Developing a Method for Success

Contract manufacturing services for GMP-grade RNA are in demand.

RNA’s Expanding Horizons

Topic

Articles

LGM Pharma will offer contract analytical testing and stability services to pharmaceutical developers and manufacturers.

LGM Pharma Launches Analytical Services for Drug Developers and Manufacturers

The extended manufacturing agreement between Pinteon and Lonza enables future clinical production of PNT001, a novel Tau antibody therapeutic that targets Alzheimer's disease and traumatic brain injury.

Pinteon and Lonza Extend Collaboration for Manufacturing Antibody Therapeutic

Selexis and KBI Biopharma will use integrated services to advance Immatics’ TCR bispecifics drug development program to the IND stage.

Selexis and KBI Biopharma Partner with Immatics to Advance T-Cell Bispecific Program

Susan Haigney is managing editor of BioPharm International, susan.haigney@ubm.com.

CMOs and CDMOs adjust business processes as demand for COVID-19 treatments and non-pandemic related therapies puts pressure on the bio/pharma industry.

Balancing Pressing Priorities

CDMO Yposkesi will increase its current gene therapy vector capacity through French government’s “Plan de Relance” scheme.

Yposkesi’s Bioproduction Project Selected for French Government Investment 

The companies have entered into an agreement to develop processes for a novel immunotherapy protein.

SelectImmune and Lonza to Develop Immunotherapeutic Drug Candidate

The companies will utilize the Cocoon Platform for clinical point-of-care manufacturing.

Lonza and CellPoint Collaborate to Develop T-cell Based Therapies

VIVEbiotech has opened its new lentiviral vector manufacturing facilities in Spain, expanding capacity for lentiviral vectors for use in cell and gene therapies.

VIVEbiotech Launches Lentiviral Vector Manufacturing Plant for Cell and Gene Therapies

AGC Biologics has partnered with BioNTech to further supply plasmid DNA starting material from its Heidelberg, Germany, facility for the Pfizer-BioNTech COVID-19 vaccine.

AGC Biologics to Supply More Plasmid DNA for Pfizer-BioNTech COVID-19 Vaccine

Catherine Liloia, Catherine.Liloia@ppd.com, is director at PPD Laboratories’ GMP cell lab.

Benjamin Ziehr, PhD, is senior group leader at PPD Laboratories’ GMP cell lab.

Derrick McVicker, PhD, is group leader at PPD Laboratories’ GMP cell lab.

Yat Yee Wong, PhD, is group leader at PPD Laboratories’ GMP cell lab.

Esteban Carrillo, PhD, is senior research scientist at PPD Laboratories’ GMP cell lab.

Alexander Rodriguez, PhD, is research scientist at PPD Laboratories’ GMP cell lab.

The increased number of regulatory filings for cell and gene therapies requires reevaluation of bioassay methods because of their complexity.